Medicines for Malaria Venture

Our work

We discover, develop and deliver malaria medicines tailored to the populations they serve.

Read our story

Developing antimalarials to save lives

15

medicines

13.6

million deaths averted

8

SDGs furthered by our work

Latest news

World Malaria Report 2023: “We are at the crossroads of opportunities and challenges,” says WHO

The report reveals some important global challenges, including climate change, as progress against the disease continues to stagnate.

30 November 2023

Africa-Europe partnership launches study to evaluate emergency response tools for severe malaria in highly isolated rural settings

Africa-Europe partnership launches study to evaluate emergency response tools for severe malaria in highly isolated rural settings.

27 November 2023

MMV congratulates Professor David Fidock, new President-Elect of ASTMH

MMV is delighted to hear of Dr. David Fidock’s selection as President-Elect of The American Society of Tropical Medicine and Hygiene (ASTMH).

13 November 2023

Countries can hold the line against antimalarial resistance in Africa - but we must act now

Since 2020, several studies have confirmed the emergence of partial artemisinin resistance – a delay in the time it takes for treatments to successfully clear the parasite - in a growing number of African countries. This presents a significant threat to efforts to control and eliminate malaria in Africa.

13 November 2023

Digital Annual Report 2022

Defeating malaria while reinforcing diversity, equity and inclusion

Throughout 2022, MMV continued working with our partners to bring forward antimalarials to protect and cure the world’s most underserved populations, enhance control efforts and progress toward the eventual eradication and elimination of the disease globally. Our latest annual report offers an in-depth overview of MMV’s activities, achievements and financial statements for 2022. Read more.

Digital Annual Report 2022

Throughout 2022, MMV continued working with our partners to bring forward antimalarials to protect and cure the world’s most underserved populations, enhance control efforts and progress toward the eventual eradication of the disease globally. Our latest annual report offers an in-depth overview of MMV’s activities, achievements and financial statements for 2022. Read more.

Gender equity

A gender-transformative approach

Women and girls are uniquely affected by malaria's health, economic and societal impacts. Malaria means a heightened risk of morbidity and mortality for pregnant women and girls and their newborns. This, in turn, contributes to keeping women and girls away from school and work, exacerbating gender inequalities in education and in the workplace, and ultimately intensifying gendered power imbalances in society. MMV works to remedy this with the Malaria in Mothers and Babies (MiMBa) strategy. Read more.

Health systems strengthening

Smiling children sitting in front of a mosquito net

Preparing for the next global disease outbreak

Before the COVID-19 pandemic, the term “global health” was often used with reference to low-and-middle-income countries. If the past two years have taught us anything, it is that we are all “global health”—North or South, microbes and particles connect us all, yet resources are unevenly distributed. Investments in combatting diseases that often occur amongst the poorest populations allow countries to build more resilient health systems. These systems can be deployed in response to the next global health emergency. Read more.